Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes (ATORVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00520585|
Recruitment Status : Unknown
Verified August 2007 by Masaryk University.
Recruitment status was: Not yet recruiting
First Posted : August 24, 2007
Last Update Posted : August 24, 2007
The aim of this study is to evaluate influence of atorvastin on the repolarisation phase of cardiomyocytes. If there is any, it could be a part of positive "non-lipid" effect of statins in therapy of ischaemic heart disease.
Study hypothesis: atorvastin will decrease heterogeneity of repolarisation of cardiomyocytes in comparison with placebo
|Condition or disease||Intervention/treatment|
|Heterogeneity of Cardiomyocytes Repolarisation Autonomic Changes of Cardiomyocytes Repolarisation||Drug: atorvastatin|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes|
|Study Start Date :||August 2007|
|Estimated Study Completion Date :||November 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520585
|Contact: Ondrej Toman, MDfirstname.lastname@example.org|
|Principal Investigator:||Ondrej Toman, MD||University Hospital Brno, Department of Cardiology, Brno, Czech Republic|